Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%
NCT ID: NCT00437151
Last Updated: 2022-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
61 participants
INTERVENTIONAL
2006-06-30
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris
NCT00696449
Effect of Samples on Acne Treatment With Epiduo® Gel
NCT01504204
Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel
NCT01095640
Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
NCT00671749
Efficacy of Epiduo and Treatment Adherence of Adolescent Patients With Inflammatory Acne
NCT01220102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
More frequent than normal office visits
More frequent than normal office visits
Mode of patient reminder
2
Electronic reminders (voice, e-mail, text messages)
Electronic reminders (voice, e-mail, text messages)
Mode of patient reminder
3
Parental involvement / intervention reminders
Parenteral involvement / intervention reminders
Mode of patient reminder
4
No intervention or reminders
No intervention or reminders
Mode of patient reminder
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
More frequent than normal office visits
Mode of patient reminder
Electronic reminders (voice, e-mail, text messages)
Mode of patient reminder
Parenteral involvement / intervention reminders
Mode of patient reminder
No intervention or reminders
Mode of patient reminder
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
13 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Galderma Laboratories, L.P.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronald W Gottschalk, MD
Role: STUDY_DIRECTOR
Galderma Laboratories, LP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wake Forest School of Medicine
Winston-Salem, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US10022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.